Brief: Moonlake Completes Patient Randomization For Phase 2 Trial In Active Psoriatic Arthritis
25/07/2023 15:25
July 25 (Reuters) - MoonLake Immunotherapeutics
MLTX.O :
* MOONLAKE COMPLETES PATIENT RANDOMIZATION AHEAD OF SCHEDULE
FOR
ITS PHASE 2 TRIAL IN ACTIVE PSORIATIC ARTHRITIS (PSA) AND
PROVIDES CALENDAR OF NEXT READOUTS
* MOONLAKE IMMUNOTHERAPEUTICS - TOP-LINE RESULTS OF ARGO
TRIAL ARE
NOW EXPECTED IN FIRST HALF OF NOVEMBER 2023
Source text for Eikon: ID:nGNX4x4T6Q
Further company coverage: MLTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on MoonLake Immunotherapeutics
See all newsMoonLake jumps as AbbVie's weak skin drug data eases competition fears
Brief: Moonlake Immunotherapeutics Files For Mixed Shelf Offering, Size Not Disclosed
MoonLake Immunotherapeutics reports results for the quarter ended June 30 - Earnings Summary
MoonLake's psoriatic arthritis drug meets key goals in late-stage trial (updated)
MoonLake's psoriatic arthritis drug meets key goals in late-stage trial